Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.59 |
| ▸ | DHFR | P00374 | 3/20 | 0.47 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097044 | 0.88 | ADORA1 (0.46) | ADORA2AADORA1DHFRTYMSSMN1; SMN2 | |
| SCHEMBL4101625 | 0.86 | POLB (0.51) | ADORA2AADORA1FYNSMN1; SMN2 | |
| SCHEMBL4106777 | 0.84 | SLC10A2 (0.46) | ADORA2AADORA1DHFRFYN | |
| SCHEMBL4113768 | 0.84 | ADORA2A (0.46) | ADORA2AADORA1 | |
| SCHEMBL4101150 | 0.82 | ADORA2A (0.63) | ADORA2AADORA1DHFR | |
| SCHEMBL4108241 | 0.82 | DHFR (0.47) | ADORA2AADORA1DHFRLMNASMN1; SMN2 | |
| SCHEMBL4108639 | 0.82 | ADORA2A (0.63) | ADORA2AADORA1LMNASMN1; SMN2 | |
| SCHEMBL4115794 | 0.82 | ADORA1 (0.43) | ADORA2AADORA1DHFRSMN1; SMN2 | |
| SCHEMBL4097136 | 0.81 | DHODH (0.48) | ADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL4095769 | 0.81 | ADORA1 (0.48) | ADORA2AADORA1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | claimed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | PNPO, PNP, DPYD | ADORA2A 165/4885ADORA1 163/4885DHFR 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.